tolvaptan has been researched along with spironolactone in 11 studies
| Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) | Studies (spironolactone) | Trials (spironolactone) | Recent Studies (post-2010) (spironolactone) |
|---|---|---|---|---|---|
| 967 | 172 | 786 | 7,222 | 960 | 1,923 |
| Protein | Taxonomy | tolvaptan (IC50) | spironolactone (IC50) |
|---|---|---|---|
| Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
| Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
| Estrogen receptor | Homo sapiens (human) | 5.702 | |
| Glucocorticoid receptor | Homo sapiens (human) | 4.0745 | |
| Progesterone receptor | Homo sapiens (human) | 1.675 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 0.0315 | |
| Androgen receptor | Homo sapiens (human) | 0.3585 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.406 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 1.9025 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 6.92 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Maggioni, AP | 1 |
| Goto, A; Matsumoto, M; Nakamura, M; Sakaida, I; Terai, S | 1 |
| Iwahasi, T; Iwahori, A; Iwasaki, T; Koizumi, N; Maruno, K; Matsuyama, K; Nishibe, T; Ogino, H; Takahashi, S; Toguchi, K | 1 |
| Izumi, N; Kurosaki, M; Nakanishi, H | 1 |
| Goya, T; Kato, M; Kohjima, M; Kotoh, K; Masumoto, A; Miyazaki, M; Motomura, K; Senjyu, T; Tanaka, K; Yada, M | 1 |
| Iida, Y; Shimizu, H; Yoshitake, A | 1 |
| Hirai, H; Hosono, M; Kaku, D; Kubota, Y; Nakahira, A; Sasaki, Y; Shibata, T; Suehiro, S; Suehiro, Y | 1 |
| Ishihara, T; Isoai, A; Iwasa, M; Kato, M; Kobayashi, R; Soneda, N; Takei, Y; Torii, N | 1 |
| Kajimoto, K; Otsubo, S | 1 |
| Abe, H; Arai, T; Atsukawa, M; Chuma, M; Fukunishi, S; Hattori, N; Hiraoka, A; Iio, E; Ikegami, T; Itokawa, N; Iwakiri, K; Iwasa, M; Kato, K; Kondo, C; Kumada, T; Michitaka, K; Nakagawa-Iwashita, A; Nozaki, A; Okubo, H; Okubo, T; Senoh, T; Tada, T; Takaguchi, K; Takei, Y; Tanaka, Y; Tani, J; Toyoda, H; Tsubota, A; Tsutsui, A; Uojima, H; Watanabe, T; Yokohama, K; Yoshida, Y | 1 |
2 review(s) available for tolvaptan and spironolactone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Management of ascites in cirrhotic patients.
Topics: Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Ascites; Benzazepines; Diuretics; Humans; Japan; Liver Cirrhosis; Practice Guidelines as Topic; Receptors, Vasopressin; Signal Transduction; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone; Tolvaptan; Vasopressins | 2017 |
2 trial(s) available for tolvaptan and spironolactone
| Article | Year |
|---|---|
Effects of short-term administration of tolvaptan after open heart surgery.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Cardiac Surgical Procedures; Diuretics; Drug Monitoring; Drug Therapy, Combination; Female; Fluid Shifts; Furosemide; Humans; Male; Middle Aged; Postoperative Complications; Spironolactone; Tolvaptan; Treatment Outcome; Urinalysis | 2016 |
Efficacy and Safety Evaluation of Tolvaptan on Management of Fluid Balance after Cardiovascular Surgery Using Cardiopulmonary Bypass.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Cardiopulmonary Bypass; Cardiovascular Surgical Procedures; Diuretics; Drug Monitoring; Drug Therapy, Combination; Female; Furosemide; Humans; Kidney Function Tests; Male; Middle Aged; Postoperative Complications; Spironolactone; Tolvaptan; Treatment Outcome; Water-Electrolyte Balance; Water-Electrolyte Imbalance | 2016 |
7 other study(ies) available for tolvaptan and spironolactone
| Article | Year |
|---|---|
[Multination clinical trials: what is the relevance and what are the lessons from across-country differences?].
Topics: Acute Coronary Syndrome; Adenosine; Americas; Benzazepines; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Ethnicity; Europe; Female; Georgia (Republic); Heart Failure; Humans; Internationality; Male; Metoprolol; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Russia; Sample Size; Spironolactone; Ticagrelor; Ticlopidine; Tolvaptan | 2014 |
Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites.
Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; Furosemide; Humans; Liver Cirrhosis; Male; Spironolactone; Tolvaptan | 2015 |
Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Carcinoma, Hepatocellular; Disease Progression; Diuretics; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Female; Furosemide; Humans; Liver; Liver Failure; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Spironolactone; Tolvaptan; Treatment Outcome | 2017 |
Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement.
Topics: Administration, Oral; Aged; Antidiuretic Hormone Receptor Antagonists; Aortic Aneurysm, Thoracic; Blood Vessel Prosthesis Implantation; Drug Administration Schedule; Drug Therapy, Combination; Female; Furosemide; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Retrospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone; Time Factors; Tolvaptan; Treatment Outcome; Urination; Water-Electrolyte Balance; Weight Loss | 2019 |
Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Ascitic Fluid; Diuretics; Female; Fluid Therapy; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Product Surveillance, Postmarketing; Serum Albumin; Spironolactone; Tolvaptan | 2019 |
Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report.
Topics: Acute Disease; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Aortic Valve Stenosis; Cardiomyopathy, Hypertrophic; Drug Therapy, Combination; Dyspnea; Female; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Tolvaptan | 2019 |
Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema.
Topics: Adult; Aged; Aged, 80 and over; Diuretics; Drug Therapy, Combination; Edema; Female; Furosemide; Humans; Liver Cirrhosis; Liver Diseases; Male; Middle Aged; Prognosis; Retrospective Studies; ROC Curve; Spironolactone; Survival Rate; Time Factors; Tolvaptan | 2020 |